An Open Label Study to Assess the Effect of a Combination of Avastin and Docetaxel and Sequential Chemotherapy on Pathological Response in Patients With Primary Operable HER2 Negative Breast Cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Percentage of patients with pathological complete response in breast and lymph nodes
Event driven
No
Clinical Trials
Study Director
Hoffmann-La Roche
Spain: Agencia Espanola del medicamento (AEM)
ML20382
NCT00559754
December 2007
September 2010
Name | Location |
---|